Healthicare vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Healthicare
Best for buyers who want a transparent, named-clinician + named-pharmacy compounded GLP-1 option in 44 statesStarting at $148/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Healthicare | Wisp |
|---|---|---|
| Overall Score | ✓7.1/10 | 7.0/10 |
| Starting Price | ✓$148/mo | $225/mo |
| Editorial Rating | ✓3.6 ★ /5 | 3.5 ★ /5 |
| Features | ✓7 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Healthicare
Pros
- ✓Both compounded and full brand-name GLP-1 menu (Ozempic, Wegovy, Mounjaro, Zepbound) on one platform
- ✓Pharmacy partner is publicly named: F&F Pharmacies Inc. dba Jungle Jim's Pharmacy, 5484 Dixie Highway, Fairfield, OH 45014, (877) 858-3784
- ✓Clinical lead is publicly named: Dr. Jonah Mink, 618.740.4204, Beluga Health
- ✓Compounded semaglutide first dose at $147.90/mo is on the lower end of the segment
Cons
- ✗Not available in 6 states: CA, NV, NJ, NC, TX, MA, MS, NH, WV, DE (verify the explicit list before sending readers)
- ✗Brand-name first-month pricing of $1,199.99–$1,299.99 is at or above retail without insurance — most of the value here is on the compounded tier
- ✗Brand ownership: 'Sunshine Health Studios Inc.' is referenced in the footer — relationship to the healthicare.com domain owner needs independent confirmation
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Healthicare edges out Wisp with a higher overall score of 7.1/10 and is particularly strong for buyers who want a transparent, named-clinician + named-pharmacy compounded GLP-1 option in 44 states. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.